| mln. INR | 2011 | 2012 | 2013 | 2014 | 2015 | 2015/2014 |
|---|---|---|---|---|---|---|
| P&L | ||||||
| Revenue | 3,631 | 4,088 | 4,686 | 5,416 | 4,497 | -17.0% |
| EBITDA | 903 | 1,031 | 1,201 | 1,382 | 869 | -37.1% |
| Net Income | 462 | 471 | 573 | 643 | 45 | -92.9% |
| Balance Sheet | ||||||
| Cash | 31 | 10 | 33 | 7 | -100.0% | |
| Short Term Debt | 632 | 1,212 | 957 | 1,101 | -100.0% | |
| Long Term Debt | 1,237 | 991 | 1,291 | 1,400 | -100.0% | |
| Cash flow | ||||||
| Capex | 965 | 950 | 1,040 | 947 | -100.0% | |
| Ratios | ||||||
| Revenue growth | -33.4% | 12.6% | 14.6% | 15.6% | -17.0% | |
| EBITDA growth | 19.6% | 14.2% | 16.5% | 15.1% | -37.1% | |
| EBITDA Margin | 24.9% | 25.2% | 25.6% | 25.5% | 19.3% | -6.2% |
| Net Income Margin | 12.7% | 11.5% | 12.2% | 11.9% | 1.0% | -10.9% |
| CAPEX, % of revenue | 26.6% | 23.2% | 22.2% | 17.5% | -17.5% | |
| ROIC | 18.3% | 15.7% | 14.9% | 14.4% | -14.4% | |
| ROE | 22.7% | 17.3% | 16.7% | 15.3% | -15.3% | |
| Net Debt/EBITDA | 2.0x | 2.1x | 1.8x | 1.8x | 0.0x | -1.8x |
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Mangalam Drugs & Organics ($MANGALAM) | 16.6% | -18.2% | -2.1% | 79.8% | |
| Sun Pharmaceutical Industries ($SUNPHARMA) | 39.9% | 40.4% | 42.4% | 70.2% | |
| Marksans Pharma ($MARKSANS) | 16.7% | 23.3% | 43.3% | 26.8% | |
| Torrent Cables ($TORRCABS) | 27.5% | 17.4% | -42.9% | 26.5% | |
| Lincoln Pharmaceuticals ($LINCOPH) | 6.3% | 3.8% | 8.5% | 25.9% | |
| Median (37 companies) | -16.1% | 16.7% | 14.9% | 12.6% | 10.4% |
| Venus Remedies ($VENUSREM) | 12.6% | 14.6% | 15.6% | -17.0% | |
| Top | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Dr.Reddy'S Laboratories ($DRREDDY) | 52.1% | 57.4% | 57.6% | ||
| Omega Laboratories ($OMEGALAB) | 0.0% | 0.0% | 0.0% | 0.0% | |
| Median (2 companies) | 46.9% | 26.1% | 28.7% | 28.8% | |
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Divi'S Laboratories ($DIVISLAB) | 38.1% | 37.2% | 38.2% | 40.2% | 37.4% |
| Hester Biosciences ($HESTERBIO) | 32.9% | ||||
| Sun Pharmaceutical Industries ($SUNPHARMA) | 34.3% | 40.8% | 44.3% | 44.9% | 29.2% |
| Natco Pharma ($NATCOPHARM) | 21.3% | 21.5% | 23.2% | 24.9% | 26.2% |
| Dr.Reddy'S Laboratories ($DRREDDY) | 21.7% | 25.8% | 22.9% | 25.1% | 23.2% |
| Median (46 companies) | 16.2% | 12.7% | 12.8% | 14.3% | 13.0% |
| Venus Remedies ($VENUSREM) | 24.9% | 25.2% | 25.6% | 25.5% | 19.3% |
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Claris Lifesciences ($CLARIS) | 32.5% | 58.1% | 42.9% | 103.1% | |
| Wintac ($WINTAC) | 22.8% | ||||
| Hester Biosciences ($HESTERBIO) | 21.5% | ||||
| Ipca Laboratories ($IPCALAB) | 10.3% | 11.2% | 8.3% | 11.6% | 17.8% |
| Natco Pharma ($NATCOPHARM) | 20.0% | 24.4% | 16.3% | 14.4% | 14.1% |
| Median (31 companies) | 7.3% | 7.7% | 7.5% | 5.7% | 6.2% |
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Marksans Pharma ($MARKSANS) | -25.8% | -142.4% | 34.9% | 33.8% | 41.2% |
| Alembic Pharmaceuticals ($APLLTD) | 27.5% | 29.1% | 41.5% | 35.7% | |
| Jenburkt Pharmaceuticals ($JENBURPH) | 43.6% | 34.1% | 29.0% | 32.4% | 35.3% |
| Abbott India ($ABBOTINDIA) | 36.0% | 29.6% | 26.9% | 30.5% | 34.2% |
| Divi'S Laboratories ($DIVISLAB) | 25.6% | 30.6% | 30.4% | 32.3% | 30.5% |
| Median (53 companies) | 13.5% | 13.7% | 13.2% | 15.6% | 13.3% |
| Venus Remedies ($VENUSREM) | 18.3% | 15.7% | 14.9% | 14.4% | |
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Jubilant Life Sciences Limited ($JUBILANT) | 5.3x | 4.0x | 3.5x | 3.5x | 6.4x |
| Shasun Pharmaceuticals ($SHASUNPHAR) | 4.5x | 2.8x | 4.5x | 6.0x | 6.2x |
| Claris Lifesciences ($CLARIS) | 1.5x | 1.9x | 1.1x | 1.8x | 3.2x |
| Dishman Pharmaceuticals & Chemicals ($DISHMAN) | 3.7x | 3.6x | 2.6x | 2.3x | 2.9x |
| Neuland Laboratories ($NEULANDLAB) | 4.9x | 4.2x | 3.5x | 2.6x | 2.6x |
| Median (42 companies) | 1.5x | 1.4x | 1.2x | 0.3x | 0.6x |
| Venus Remedies ($VENUSREM) | 2.0x | 2.1x | 1.8x | 1.8x | 0.0x |
